Myeloproliferative Neoplasms

Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.

Pankit Vachhani, MD, discusses the ongoing investigation of navtemadlin either alone or as an add-on to ruxolitinib for patients with myelofibrosis.

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.